At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time

AMP 2020 Annual Meeting and Expo

From Leo O’Connor of LabPulse.com At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour. The SeptiCyte Rapid test is different from almost all other sepsis tests on the market by means of its operation directly…

Read More

CEO Rolland Carlson: When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems

Immunexpress CEO Rolland Carlson was recently featured on HITConsultant, which provides healthcare technology news, analysis and insights for healthcare executives, physicians and providers. “US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating how to integrate the medical…

Read More

Interview with Dr Rolland Carlson and Dr Richard Brandon

Drug Target Review screenshot

The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular diagnostics and how their biomarker signature discovery approach has aided them in creating an assay for the detection of sepsis. Source: Drug Target…

Read More

A Paradigm Shift in Sepsis Diagnostics

Technology Networks

By Anna MacDonald of Technology Networks Immunexpress is advancing next-generation clinical sepsis diagnosis tests for use in emergency room and intensive care unit settings. The company’s lead test SeptiCyte® RAPID is clinically validated and has received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. It is the first gene expression host response…

Read More

Tips For Obtaining Your 510(k) FDA Clearance

Med Device Online

By Rolland Carlson, Ph.D., CEO, Immunexpress Our SeptiCyte RAPID clinical test received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. Sepsis is a life-threatening medical condition. Every minute counts for these patients in the ER and ICU. Clinicians in these settings need processes to distinguish sepsis patients from infection-negative systemic inflammation and…

Read More

10News Brisbane

SeptiCyte RAPID is highlighted in this 10News First Brisbane interview. The country’s largest pediatric sepsis study at the Queensland Children’s Hospital is working on finding simple diagnostic blood tests for the 5,000 Australians a year and robs others of their limbs.

Read More